A comparison of consecutive off-pump versus conventional coronary artery bypass

Autor: Mn, Kavarana, As, Asher, Alessandro BARBONE, Williams MR, Jm, Faber, Ad, Weinberg, Ab, Isidro, Mc, Oz, Bc, Esrig

Publikováno v: Europe PubMed Central

Coronary revascularization on the beating heart is an attractive alternative to conventional coronary artery bypass grafts (CCABG), but remains controversial. Our study compares the outcomes of consecutive patients undergoing off-pump CABG (OPCABG) w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7061bc3dcdc05057e62d6e5dd26c30c4
https://pubmed.ncbi.nlm.nih.gov/11544624

Pain relief in refractory fibromyalgia after vestibulocortical stimulation: an open-label pilot trial.

Autor: Kaplan MH; Division of Rheumatology, Mount Sinai Hospital, New York, NY 10019, United States., Zhou CH; Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Pittsburgh, PA 15232, United States., Carroll E; Division of Rheumatology, Mount Sinai Hospital, New York, NY 10019, United States., Weinberg AD; Population Health Science & Policy, Mount Sinai Hospital, New York, NY 10019, United States., Clauw DJ; Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI 48106-5737, United States., Ngô TT; RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland 4029, Australia., Tassiulas I; Division of Rheumatology, Mount Sinai Hospital, New York, NY 10019, United States.

Publikováno v: Pain medicine (Malden, Mass.) [Pain Med] 2024 Mar 01; Vol. 25 (3), pp. 252-254.

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.

Autor: Hirschhorn D; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Budhu S; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Kraehenbuehl L; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Gigoux M; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Schröder D; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Chow A; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Ricca JM; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Gasmi B; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., De Henau O; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Mangarin LMB; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Li Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hamadene L; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Flamar AL; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Choi H; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Cortez CA; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Liu C; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Holland A; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Schad S; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Schulze I; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Betof Warner A; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA., Hollmann TJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Arora A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Panageas KS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rizzuto GA; Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Duhen R; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Weinberg AD; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Spencer CN; Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Ng D; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., He XY; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Albrengues J; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Redmond D; Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Egeblad M; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Wolchok JD; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA; Department of Medicine and Graduate Schools, Weill Cornell Medicine, New York, NY, USA., Merghoub T; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA; Department of Medicine and Graduate Schools, Weill Cornell Medicine, New York, NY, USA. Electronic address: tmerghoub@med.cornell.edu.

Publikováno v: Cell [Cell] 2023 Mar 30; Vol. 186 (7), pp. 1432-1447.e17.

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors.

Autor: Duhen R; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Fesneau O; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Samson KA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Frye AK; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Beymer M; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Rajamanickam V; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Ross D; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Tran E; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Bernard B; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA., Weinberg AD; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.; AgonOx Inc., Portland, Oregon, USA., Duhen T; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2022 Jun 15; Vol. 132 (12).

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.

Autor: Duhen R; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. rebekka.duhen@providence.org., Ballesteros-Merino C; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Frye AK; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Tran E; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Rajamanickam V; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Chang SC; Medical Data Research Center, Providence Saint Joseph's Health, Portland, OR, USA., Koguchi Y; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Bifulco CB; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.; Molecular Genomics Laboratory, Providence St. Joseph Health, Portland, OR, USA., Bernard B; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Leidner RS; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Curti BD; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Fox BA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Urba WJ; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Bell RB; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Weinberg AD; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. andrew.weinberg@providence.org.; AgonOx, Inc., Portland, OR, USA. andrew.weinberg@providence.org.

Publikováno v: Nature communications [Nat Commun] 2021 Feb 16; Vol. 12 (1), pp. 1047. Date of Electronic Publication: 2021 Feb 16.